Mobile

A study to evaluate the efficacy and safety of Apremilast, Etanercept and placebo, in subjects with moderate to severe plaque psoriasis

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-000859-14

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the clinical efficacy and safety of oral apremilast 30 mg twice a day (BID) compared with placebo, in subjects with moderate to severe plaque psoriasis at Week 16

Critère d'inclusion

  • Moderate to Severe Plaque Psoriasis

Liens